Cargando…

Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy

BACKGROUND: Adjuvant chemotherapy in patients with resected esophageal squamous cell cancer (ESCC) remains controversial for its uncertain role in improving overall survival (OS). Nucleotide excision repair (NER) removes DNA-adducts in tumor cells induced by the platinum-based chemotherapy and thus...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Fei, Zhu, Meiling, Wang, Mengyun, Qiu, Lixin, Cheng, Lei, Jia, Ming, Xiang, Jiaqing, Wei, Qingyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888614/
https://www.ncbi.nlm.nih.gov/pubmed/27246611
http://dx.doi.org/10.1186/s12967-016-0903-z
_version_ 1782434873371262976
author Zhou, Fei
Zhu, Meiling
Wang, Mengyun
Qiu, Lixin
Cheng, Lei
Jia, Ming
Xiang, Jiaqing
Wei, Qingyi
author_facet Zhou, Fei
Zhu, Meiling
Wang, Mengyun
Qiu, Lixin
Cheng, Lei
Jia, Ming
Xiang, Jiaqing
Wei, Qingyi
author_sort Zhou, Fei
collection PubMed
description BACKGROUND: Adjuvant chemotherapy in patients with resected esophageal squamous cell cancer (ESCC) remains controversial for its uncertain role in improving overall survival (OS). Nucleotide excision repair (NER) removes DNA-adducts in tumor cells induced by the platinum-based chemotherapy and thus may modulate efficacy of the treatment. The present study evaluated if single nucleotide polymorphisms (SNPs) of NER genes were prognostic biomarkers in ESCC patients treated with platinum-based adjuvant chemotherapy (PAC). METHODS: The analysis included 572 patients, for whom six SNPs of NER genes [i.e., XPC (rs1870134 and rs2228001), ERCC2/XPD rs238406 and ERCC5/XPG (rs2094258, rs2296147 and rs873601)] were detected with the TaqMan assay. Kaplan–Meier analyses and Cox proportional hazards models were used to evaluate their associations with disease free survival (DFS) and OS of these ESCC patients receiving PAC. Receiving operating characteristic curve analysis was used to evaluate the role of the risk genotypes in the DFS and OS. RESULTS: We found that ERCC5/XPG rs2094258 and rs873601 and ERCC2/XPD rs238406 SNPs were independently associated with poorer DFS and OS of ESCC patients [ERCC5/XPG rs2094258: CT+TT vs. CC: adjusted hazards ratio (adjHR) = 1.68 and P = 0.012 for DFS; adjHR = 1.99 and P = 0.0001 for OS; ERCC5/XPG rs873601: GA+GG vs. AA: adjHR = 1.59 and P = 0.024 for DFS; adjHR = 1.91 and P = 0.0005 for OS; ERCC2/XPD rs238406: TT vs. GG+GT: adjHR = 1.43 and P = 0.020 for DFS; adjHR = 1.52 and P = 0.008 for OS]. These HRs increased as the number of risk genotypes increased in the combined analysis. The model combining the risk genotypes with clinical characteristics or the TNM stage system was better in predicting outcomes in ESCC patients with PAC. CONCLUSION: SNPs of ERCC2/XPD and ERCC5/XPG may independently and jointly predict survival of ESCC patients treated with PAC in this study population. Further validation in other study populations is warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-016-0903-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4888614
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48886142016-06-02 Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy Zhou, Fei Zhu, Meiling Wang, Mengyun Qiu, Lixin Cheng, Lei Jia, Ming Xiang, Jiaqing Wei, Qingyi J Transl Med Research BACKGROUND: Adjuvant chemotherapy in patients with resected esophageal squamous cell cancer (ESCC) remains controversial for its uncertain role in improving overall survival (OS). Nucleotide excision repair (NER) removes DNA-adducts in tumor cells induced by the platinum-based chemotherapy and thus may modulate efficacy of the treatment. The present study evaluated if single nucleotide polymorphisms (SNPs) of NER genes were prognostic biomarkers in ESCC patients treated with platinum-based adjuvant chemotherapy (PAC). METHODS: The analysis included 572 patients, for whom six SNPs of NER genes [i.e., XPC (rs1870134 and rs2228001), ERCC2/XPD rs238406 and ERCC5/XPG (rs2094258, rs2296147 and rs873601)] were detected with the TaqMan assay. Kaplan–Meier analyses and Cox proportional hazards models were used to evaluate their associations with disease free survival (DFS) and OS of these ESCC patients receiving PAC. Receiving operating characteristic curve analysis was used to evaluate the role of the risk genotypes in the DFS and OS. RESULTS: We found that ERCC5/XPG rs2094258 and rs873601 and ERCC2/XPD rs238406 SNPs were independently associated with poorer DFS and OS of ESCC patients [ERCC5/XPG rs2094258: CT+TT vs. CC: adjusted hazards ratio (adjHR) = 1.68 and P = 0.012 for DFS; adjHR = 1.99 and P = 0.0001 for OS; ERCC5/XPG rs873601: GA+GG vs. AA: adjHR = 1.59 and P = 0.024 for DFS; adjHR = 1.91 and P = 0.0005 for OS; ERCC2/XPD rs238406: TT vs. GG+GT: adjHR = 1.43 and P = 0.020 for DFS; adjHR = 1.52 and P = 0.008 for OS]. These HRs increased as the number of risk genotypes increased in the combined analysis. The model combining the risk genotypes with clinical characteristics or the TNM stage system was better in predicting outcomes in ESCC patients with PAC. CONCLUSION: SNPs of ERCC2/XPD and ERCC5/XPG may independently and jointly predict survival of ESCC patients treated with PAC in this study population. Further validation in other study populations is warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-016-0903-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-31 /pmc/articles/PMC4888614/ /pubmed/27246611 http://dx.doi.org/10.1186/s12967-016-0903-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zhou, Fei
Zhu, Meiling
Wang, Mengyun
Qiu, Lixin
Cheng, Lei
Jia, Ming
Xiang, Jiaqing
Wei, Qingyi
Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy
title Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy
title_full Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy
title_fullStr Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy
title_full_unstemmed Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy
title_short Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy
title_sort genetic variants of dna repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888614/
https://www.ncbi.nlm.nih.gov/pubmed/27246611
http://dx.doi.org/10.1186/s12967-016-0903-z
work_keys_str_mv AT zhoufei geneticvariantsofdnarepairgenespredictthesurvivalofpatientswithesophagealsquamouscellcancerreceivingplatinumbasedadjuvantchemotherapy
AT zhumeiling geneticvariantsofdnarepairgenespredictthesurvivalofpatientswithesophagealsquamouscellcancerreceivingplatinumbasedadjuvantchemotherapy
AT wangmengyun geneticvariantsofdnarepairgenespredictthesurvivalofpatientswithesophagealsquamouscellcancerreceivingplatinumbasedadjuvantchemotherapy
AT qiulixin geneticvariantsofdnarepairgenespredictthesurvivalofpatientswithesophagealsquamouscellcancerreceivingplatinumbasedadjuvantchemotherapy
AT chenglei geneticvariantsofdnarepairgenespredictthesurvivalofpatientswithesophagealsquamouscellcancerreceivingplatinumbasedadjuvantchemotherapy
AT jiaming geneticvariantsofdnarepairgenespredictthesurvivalofpatientswithesophagealsquamouscellcancerreceivingplatinumbasedadjuvantchemotherapy
AT xiangjiaqing geneticvariantsofdnarepairgenespredictthesurvivalofpatientswithesophagealsquamouscellcancerreceivingplatinumbasedadjuvantchemotherapy
AT weiqingyi geneticvariantsofdnarepairgenespredictthesurvivalofpatientswithesophagealsquamouscellcancerreceivingplatinumbasedadjuvantchemotherapy